gms | German Medical Science

27th German Cancer Congress Berlin 2006

German Cancer Society (Frankfurt/M.)

22. - 26.03.2006, Berlin

Weekly high-dose 5-FU as 24h-infusion and folinic acid (AIO regimen) plus Irinotecan in patients with advanced non-resectable adenocarcinoma or squamous epithelial carcinoma of the oesophagus: interim analysis of a phase II trial

Meeting Abstract

  • corresponding author presenting/speaker Frank Boxberger - Medizinische Klinik 1, Universitätsklinikum Erlangen, Deutschland
  • Kerstin Wolff - Medizinische Klinik 1, Universitätsklinikum Erlangen
  • Valeska Brueckl - Medizinische Klinik 1, Universitätsklinikum Erlangen
  • Wolfgang Brueckl - Medizinische Klinik 1, Universitätsklinikum Erlangen
  • Cornelia Meier - Medizinische Klinik 1, Universitätsklinikum Erlangen
  • Gudrun Maennlein - Medizinische Klinik 1, Universitätsklinikum Erlangen
  • Thomas Horbach - Chirurgische Klinik, Universitätsklinikum Erlangen
  • Werner Hohenberger - Chirurgische Klinik, Universitätsklinikum Erlangen
  • Eckhart G. Hahn - Medizinische Klinik 1, Universitätsklinikum Erlangen
  • Axel Wein - Medizinische Klinik 1, Universitätsklinikum Erlangen

27. Deutscher Krebskongress. Berlin, 22.-26.03.2006. Düsseldorf, Köln: German Medical Science; 2006. DocPO179

The electronic version of this article is the complete one and can be found online at: http://www.egms.de/en/meetings/dkk2006/06dkk289.shtml

Published: March 20, 2006

© 2006 Boxberger et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.


Outline

Text

Background: At the moment of establishing the diagnosis, in approximately 50-60% of the patients with esophageal carcinoma only palliative treatment is possible due to either a locally advanced tumour growth or due to distant metastases. While adenocarcinomas of the esophagogastric junction are increasingly treated like gastric carcinomas, no palliative standard regimen is established for advanced squamous carcinomas of the oesophagus. The question should be answered whether the AIO regimen plus Irinotecan may achieve similarly positive results in esophageal carcinomas as in gastric carcinomas.

Methods: Prospective phase II trial, patients: n=20, trial start: 03/2003, chemotherapeutic regimen: Irinotecan (80 mg/m2 i.v. as 1h-infusion; d 1, 8, 15, 22, 29, 36, qd 57) as well as folinic acid (500 mg/m2 i.v.) together with 5-Fluorouracil (2000 mg/m2 i.v.; d 1, 8, 15, 22, 29, 36, qd 57) as 24h-infusion via port catheter.

Results: n=16 (adenocarcinomas: n=8, squamous epithelial carcinomas: n=8); median age: 59,3 (44-72) years; men/women: 13/3; ECOG 0/1/2: 4/11/1; chemotherapeutic applications: 314. Evaluable in terms of toxicity: n=16. Higher grade toxicity: grade III diarrhea: n=2, grade III hyponatremia: n=1, thrombosis of the vena subclavia: n=1, grade III stomatitis: n=1, ischemic lesion of the brain stem: n=1. Two patients died after 2 chemotherapeutic applications with known peritoneal carcinomatosis and high tumour burden. Evaluable in terms of response: n=13. PR: n=7 (54%), SD: n=4 (31%), PD: n=2 (15%).

Conclusion: The AIO regimen plus Irinotecan is excellently manageable on an outpatient basis in a multimorbid patient group and shows high efficacy in both adenocarcinomas and squamous epithelial carcinomas of the oesophagus. Final results, however, particularly in terms of median survival, still remain to be seen.